5 results about "Quetiapine" patented technology

This invention belongs to the field of SNP site detection technology for guiding the use of second-generation antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T allele, an upstream primer SEQ ID NO:2 that specifically amplifies the mutant C allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a mutant probe SEQ ID NO:5. This invention assesses the genetic risk of weight gain and metabolic disorders in patients with mental illness after taking second-generation antipsychotic drugs such as risperidone, quetiapine, amisulpride, and paliperidone through rapid and accurate genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.

The invention relates to a liquid formulation, in particular to a suspension, of quetiapine or a pharmaceutically acceptable salt thereof, methods for its preparation and its use in medicine, in particular for the treatment of mental, behavioural and / or mood conditions.

The invention relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injections carrying novel artificial chemical genetics receptor gene sequences, and a combinatorial chemical genetics scheme formed by the injections and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The present invention provides an injectable pharmaceutical composition for subcutaneous or intramuscular administration comprising quetiapine or a pharmaceutically acceptable salt thereof in an amount ranging from 10 to 50% w / w of the total weight of the composition; a biocompatible polymer selected from the group consisting of an aliphatic polyester, a glycosaminoglycan, a O-substituted cellulose derivative, or a pharmaceutically acceptable salt of any of them, and any mixture thereof; and a polar solvent; wherein the weight ratio of quetiapine or the pharmaceutically acceptable salt thereof to the biocompatible polymer is from 70:1 to 1.5:1; and the composition is a suspension. It also relates to such compositions for use in the treatment of schizophrenia and / or bipolar disorder, wherein the treatment comprises subcutaneous or intramuscular administration of the composition to a subject in need thereof. It also relates to a kit for the preparation of the injectable pharmaceutical composition.

The present invention pertains to the technical field of pharmaceutical preparations, and provides a novel solution-type quetiapine composition for transnasal administration. In the provided composition, quetiapine is completely dissolved therein in the form of a solution and administered transnasally. Compared with oral dosage forms on the market, the provided quetiapine solution-type transnasal preparation has particularly useful pharmacokinetic and pharmacodynamic profiles. Compared with other disclosed transnasal nano-emulsion forms, the composition of the present invention still has surprising pharmacokinetic and pharmacodynamic profiles, shows good clinical application prospects, and is expected to meet unmet clinical needs. On this basis, the present invention also provides a further improved high-saturation dissolution concentration technical solution and a further improved good chemical stability technical solution for preparing the quetiapine solution-type transnasal preparation.